Catamaran Bio is developing novel, off-the-shelf CAR-NK cell therapies designed to treat a broad range of cancers, including solid tumors. Our proprietary capabilities enable us to harness the natural cancer-fighting properties of NK cells and enhance and tailor their effectiveness with the power of synthetic biology and innovative non-viral cell engineering.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 11/23/20 | $42,000,000 | Series A |
Astellas Venture Management Lightstone Ventures  Sofinnova Partners SV Health Investors Takeda Ventures | undisclosed |
